Therapeutic strategies targeting UPR aim to modulate its pathways to alleviate disease symptoms. For example, small molecules like 4-PBA and TUDCA are chemical chaperones that aid in protein folding and reduce ER stress. Inhibitors of PERK and IRE1 are also being explored to prevent excessive UPR activation, thereby protecting cells from apoptosis.
